Research
Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital
Published

Hormone replacement therapy and the risk of endometrial cancer: A systematic review

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Antihistamine use and risk of ovarian cancer: A population-based case-control study

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Practice points in gynecardiology: Abnormal uterine bleeding in premenopausal women taking oral anticoagulant or antiplatelet therapy

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Contemporary Hormonal Contraception and the Risk of Breast Cancer

    Research output: Contribution to journalComment/debateResearchpeer-review

  2. Tibolone and risk of gynecological hormone sensitive cancer

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Parental Rheumatoid Arthritis and Autism Spectrum Disorders in Offspring: A Danish Nationwide Cohort Study

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Association of Hormonal Contraception With Suicide Attempts and Suicides

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

BACKGROUND: In 1975, estrogen only was found to be associated with an increased risk of endometrial cancer. In November 2015, NICE guidelines on hormone therapy were published that did not take this risk into account.

AIM: This systematic literature review assesses the safety of estrogen plus progestin therapy according to the risk of endometrial cancer, while considering both regimen and type of progestin.

METHODS: PubMed, EMBASE and the Cochrane Library were searched, resulting in the identification of 527 published articles on menopausal women with intact uteri treated with estrogen only, estrogen plus progestin or tibolone for a minimum of one year. Risk of endometrial cancer was compared to placebo or never users and measured as relative risk, hazard or odds ratio.

RESULTS: 28 studies were included. The observational literature found an increased risk among users of estrogen alone. Continuous combined therapy showed a lower risk than sequential combined therapy. The newer marketed micronized progesterone increased the risk notably, also when administered continuously. In most studies, tibolone was associated with an increased risk.

CONCLUSION: Use of unopposed estrogen, tibolone and sequential combined therapy increases the risk of endometrial cancer. Continuous combined therapy seems risk free, but possibly not when micronized progesterone is used.

Original languageEnglish
JournalMaturitas
Volume91
Pages (from-to)25-35
Number of pages11
ISSN0378-5122
DOIs
Publication statusPublished - Sep 2016

    Research areas

  • Journal Article, Review

ID: 48286391